Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus...

Full description

Bibliographic Details
Main Authors: Kanako Shinada, Takashi Sato, Saya Moriyama, Yu Adachi, Masahiro Shinoda, Shinichiro Ota, Miwa Morikawa, Masamichi Mineshita, Takayuki Matsumura, Yoshimasa Takahashi, Masaharu Shinkai
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Viruses
Subjects:
favipiravir
COVID-19
SARS-CoV-2
neutralizing antibody
neutralizing potency index
neutralization breadth index
Online Access:https://www.mdpi.com/1999-4915/14/4/670

Internet

https://www.mdpi.com/1999-4915/14/4/670

Similar Items